Literature DB >> 3978545

Determination and characterization of hexokinase in thyroid cancer and benign neoplasms.

J N Verhagen, M C Van der Heijden, G Rijksen, P J Der Kinderen, J A Van Unnik, G E Staal.   

Abstract

Hexokinase (ADP: D-hexose-6-phosphotransferase, EC 2.7.1.1) was studied in human thyroid carcinomas (n = 11), follicular adenomas (n = 32), and normal thyroid tissue (n = 21). The specific activity was significantly increased in carcinoma (0.163 +/- 0.083 U/mg protein) compared with normal tissue (0.030 +/- 0.010 U/mg protein) (P less than 0.001). Specific activities of follicular adenomas are rather heterogeneous, but when subdivided into three groups according to histopathologic criteria, a significant difference was found between follicular adenomas group I and II and follicular adenomas group III. A lesser cellular differentiation of adenomas is indicated by the lower degree or even absence of colloid production and follicle formation. A higher proliferation rate may be assumed on the grounds of the irregularities in outline, the often defective pseudocapsule, and signs of compression of the surrounding tissue. The highest specific activity in adenomas was found in the group with the highest proliferative activity, i.e., group III, whereas the lowest specific activities were found in adenomas with the lowest grade of proliferation, i.e., group I; the former was comparable with values found in carcinomas and the latter was comparable with values found in normal thyroid tissue. An interesting difference was found when the compartmentation of hexokinase was compared in carcinomas of different degree of differentiation. In papillary carcinomas a significantly lower proportion of hexokinase (HK) is present in the cytosol in comparison to follicular and undifferentiated carcinomas. In carcinomas more HK II and less HK I was found in comparison with normal thyroid tissue. In contrast hexokinase isozyme composition and compartmentation in adenomas were not different from normal thyroid tissue.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3978545     DOI: 10.1002/1097-0142(19850401)55:7<1519::aid-cncr2820550718>3.0.co;2-k

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

1.  Effect of lentivirus-mediated shRNA inactivation of HK1, HK2, and HK3 genes in colorectal cancer and melanoma cells.

Authors:  Anna V Kudryavtseva; Maria S Fedorova; Alex Zhavoronkov; Alexey A Moskalev; Alexander S Zasedatelev; Alexey A Dmitriev; Asiya F Sadritdinova; Irina Y Karpova; Kirill M Nyushko; Dmitry V Kalinin; Nadezhda N Volchenko; Nataliya V Melnikova; Kseniya M Klimina; Dmitry V Sidorov; Anatoly Y Popov; Tatiana V Nasedkina; Andrey D Kaprin; Boris Y Alekseev; George S Krasnov; Anastasiya V Snezhkina
Journal:  BMC Genet       Date:  2016-12-22       Impact factor: 2.797

2.  Hesperetin impairs glucose uptake and inhibits proliferation of breast cancer cells.

Authors:  Yong Yang; Joy Wolfram; Kathryn Boom; Xiaohong Fang; Haifa Shen; Mauro Ferrari
Journal:  Cell Biochem Funct       Date:  2012-10-08       Impact factor: 3.685

3.  Thyroid Peroxidase Expression in Diseased Human Thyroid Glands.

Authors:  Marcus A. Lima; Valeria A. Gontijo; Marlene C. Santos; Fernando C. L. Schmitt
Journal:  Endocr Pathol       Date:  1999       Impact factor: 3.943

4.  Thyroid Peroxidase and Thyroglobulin Expression in Normal Human Thyroid Glands.

Authors:  Marcus A. Lima; Vakria A. Gontijo; Fernando C. L. Schmitt
Journal:  Endocr Pathol       Date:  1998       Impact factor: 3.943

Review 5.  Metabolic Reprogramming in Thyroid Carcinoma.

Authors:  Raquel Guimaraes Coelho; Rodrigo S Fortunato; Denise P Carvalho
Journal:  Front Oncol       Date:  2018-03-23       Impact factor: 6.244

6.  Prognostic significance of pseudocapsule status in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors.

Authors:  Wei Xi; Yingyong Hou; Xiaoyi Hu; Yu Xia; Shuai Jiang; Hang Wang; Qi Bai; Jun Hou; Jianming Guo
Journal:  Transl Androl Urol       Date:  2021-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.